Ntisec ☑️Het Zwitserse biotechbedrijf GeNeuro haalt 5 miljoen euro binnen om de onderzoeken naar #Temelimab behandeling na COVID-19 te versnellen
#LongCovid #HERV reactivatie
Corrosive DreamIn der Schweiz ist #Geneuro auf der Suche nach #LongCovid-Erkrankten, die an der Therapiestudie mit #Temelimab teilnehmen möchten. Es geht insbesondere um neurologische und psychiatrische Symptome.
Michael StinglSo wichtig, dass sich bezüglich Therapiestudien bei #LongCovid etwas tut!
In dieser Studie aus 🇨🇭 wird #Temelimab untersucht.
Temelimab ist ein monoklonaler Antikörper, der sich gegen ein Hüllenprotein von HERV-W richtet.
HERV sind in unser Genom integrierte Retroviren. Sie könnten auch bei #MECFS eine Rolle spielen.
jardinduvinAn alle Post-Covid Betroffenen in der Schweiz (und Umgebung) & deren Angehörige:
In der Schweiz startete eine Studie für ein Medikament gegen Post-Covid. Es werden 200 Patient*innen in fünf verschiedenen Spitälern aufgenommen.
Es hat noch freie Plätze!
1/6
Interesting trial.
Long-COVID personalized medicine enters Phase 2 trial using #Temelimab against #HERV virus that was induced during a SARScov2 infection in #LongCovid patients. #Anti_W_ENV
https://www.biopharma-reporter.com/Article/2022/11/22/Long-COVID-personalized-medicine-enters-Phase-2-trial#.Y33omibPgA0.twitter
Tina Meyer💙💛 #FightMS + LCovRT 🔗🐦
https://twitter.com/anthokhun/status/1595809222838599680?t=78bR_FYzcjSWK6h6oMOR8w&s=19
Very interesting, a participant in the Post-Covid study with #temelimab will tell about his journey with #CovidLong and also talk about the study he is participating in 🇨🇭. Lots of hope for #MultipleSclerosis patients too with this drug candidate 🌞.
Anthony on Twitter
“Hello à tous ! J’ai décidé de documenter à mort mon #covid et #CovidLong depuis le début mais c’était un peu le b*rdel dans mes notes. So j’ai rangé et je vais poster des articles sur un @SubstackInc (genre de blog avec newsletter). Notamment sur l’étude clinique #temelimab ⬇️”
J.H.NoyesRe: #Temelimab (Anti HERV-env)
#PathogenicCoronaviruses are known for the severe amount of #Complement component activation provoked. In keeping with that, surface Complement Regulatory Protein #CD46 inducts HERV-Env via C3b attached to SCRs 2-4. Interestingly enough, the Split Complement products produced via CD46 mediated inactivation of #C3b and #C4b are #NRP1 ligands.
CD46 & HERV-Env: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291489/
Induction of Proinflammatory Multiple Sclerosis-Associated Retrovirus Envelope Protein by Human Herpesvirus-6A and CD46 Receptor Engagement
The aberrant expression of human endogenous retrovirus (HERV) elements of the HERV-W family has been associated with different diseases, including multiple sclerosis (MS). In particular, the expression of the envelope protein (Env) from the multiple sclerosis-associated ...
@SilverGorilla2 🙏
I am not a scientist, I've read that the envelope protein of the #HERV-W #Retrovirus might be an aggravating factor in #MS and that it would also play a role in inflammatory #psychosis, as well as in min. 25% of #longcovid. All this has been published. Forseps.org has been following this trail for 10 years. A P2 trial with #temelimab targeting this protein is recruiting in 🇨🇭 Switzerland. The P2 in #MS had positive results, presented at #ECTRIMS2022#mschat
I am not a scientist, I've read that the envelope protein of the #HERV-W #Retrovirus might be an aggravating factor in #MS and that it would also play a role in inflammatory #psychosis, as well as in min. 25% of #longcovid. All this has been published. Forseps.org has been following this trail for 10 years. A P2 trial with #temelimab targeting this protein is recruiting in 🇨🇭 Switzerland. The P2 in #MS had positive results, presented at #ECTRIMS2022#mschat
AnthonyLet’s go injection de #temelimab, le cathéter est posé, j’attend la perf (de placebo ou pas😅) #LongCovid #covidlong #CovidIsNotOver merci à l’HUG pour l’étude clinique et la prise en charge au top 👌
👉An interesting paper :
"HERV-W ENV antigenemia and correlation of increased anti-SARS-CoV-2 immunoglobulin levels with post-COVID-19 symptoms."
" (...) The present study shows, for the first time, that the HERV-W ENV protein can still be actively expressed long after SARS-CoV-2 infection is resolved in post-COVID-19 condition patients.(...)"
There's a P2 clinical trial enrolling:
https://clinicaltrials.gov/ct2/show/NCT05497089
#Post-Covid #LongCovid #SARS-CoV-2 #Retrovirus #PHERV-W env #Temelimab #ClinicalTrial
